RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dr Reddy's Laboratories - Stock

Dr Reddy's Laboratories EBIT 2024

Dr Reddy's Laboratories EBIT

64.63 B INR

Ticker

DRREDDY.NS

ISIN

INE089A01023

WKN

659157

In 2024, Dr Reddy's Laboratories's EBIT was 64.63 B INR, a 22.19% increase from the 52.9 B INR EBIT recorded in the previous year.

The Dr Reddy's Laboratories EBIT history

YEAREBIT (undefined INR)
2028e85.85
2027e61.03
2026e69.12
2025e68.88
202464.63
202352.9
202235.33
202133.22
202029.91
201920.55
201812.74
201714.9
201630.8
201527.48
201426.03
201321.73
201219.17
201111.55
201010.14
20099.56
20084.39
200712.85
20061.52
2005-0.33

Dr Reddy's Laboratories Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dr Reddy's Laboratories, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dr Reddy's Laboratories from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dr Reddy's Laboratories’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dr Reddy's Laboratories. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dr Reddy's Laboratories’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dr Reddy's Laboratories’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dr Reddy's Laboratories’s growth potential.

Dr Reddy's Laboratories Revenue, EBIT and net profit per share

DateDr Reddy's Laboratories RevenueDr Reddy's Laboratories EBITDr Reddy's Laboratories Net Income
2028e372.73 B INR85.85 B INR0 INR
2027e324.38 B INR61.03 B INR49.23 B INR
2026e321.42 B INR69.12 B INR57.18 B INR
2025e304.17 B INR68.88 B INR56.35 B INR
2024280.11 B INR64.63 B INR55.78 B INR
2023246.7 B INR52.9 B INR45.07 B INR
2022215.45 B INR35.33 B INR21.83 B INR
2021190.48 B INR33.22 B INR19.52 B INR
2020175.17 B INR29.91 B INR20.26 B INR
2019154.48 B INR20.55 B INR19.5 B INR
2018142.81 B INR12.74 B INR9.47 B INR
2017141.96 B INR14.9 B INR12.92 B INR
2016155.68 B INR30.8 B INR21.31 B INR
2015150.23 B INR27.48 B INR23.36 B INR
2014134.15 B INR26.03 B INR19.63 B INR
2013118.96 B INR21.73 B INR15.27 B INR
201298.15 B INR19.17 B INR13.01 B INR
201174.97 B INR11.55 B INR9.99 B INR
201070.31 B INR10.14 B INR3.52 B INR
200969.01 B INR9.56 B INR-9.17 B INR
200849.92 B INR4.39 B INR4.38 B INR
200765.26 B INR12.85 B INR9.66 B INR
200623.63 B INR1.52 B INR1.47 B INR
200518.42 B INR-332 M INR329 M INR

Dr Reddy's Laboratories stock margins

The Dr Reddy's Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dr Reddy's Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dr Reddy's Laboratories.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dr Reddy's Laboratories's sales revenue. A higher gross margin percentage indicates that the Dr Reddy's Laboratories retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dr Reddy's Laboratories's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dr Reddy's Laboratories's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dr Reddy's Laboratories's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dr Reddy's Laboratories. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dr Reddy's Laboratories's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dr Reddy's Laboratories Margin History

Dr Reddy's Laboratories Gross marginDr Reddy's Laboratories Profit marginDr Reddy's Laboratories EBIT marginDr Reddy's Laboratories Profit margin
2028e70.69 %23.03 %0 %
2027e70.69 %18.81 %15.18 %
2026e70.69 %21.51 %17.79 %
2025e70.69 %22.64 %18.53 %
202470.69 %23.07 %19.91 %
202366.34 %21.44 %18.27 %
202262.88 %16.4 %10.13 %
202165.54 %17.44 %10.25 %
202065.68 %17.07 %11.57 %
201967.77 %13.3 %12.62 %
201868.35 %8.92 %6.63 %
201770.36 %10.5 %9.1 %
201671.33 %19.78 %13.69 %
201570.7 %18.29 %15.55 %
201468.7 %19.41 %14.63 %
201366.57 %18.26 %12.83 %
201269.75 %19.53 %13.25 %
201169.2 %15.41 %13.32 %
201063.7 %14.42 %5 %
200962.89 %13.86 %-13.29 %
200863.04 %8.79 %8.78 %
200756.21 %19.69 %14.8 %
200663.27 %6.42 %6.21 %
200566.01 %-1.8 %1.79 %

Dr Reddy's Laboratories Aktienanalyse

What does Dr Reddy's Laboratories do?

Dr. Reddy's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1984 by Dr. K. Anji Reddy. The company started as a small laboratory in Hyderabad, India and quickly grew to become one of the leading global pharmaceutical companies. History The company began as a chemical research institute specializing in the development of high-quality generics and new drugs. Dr. Reddy's Laboratories was one of the first companies in India to begin manufacturing and exporting generics on a large scale. Today, the company operates in over 100 countries worldwide and employs over 21,000 people. Business Model The company's business model focuses on developing high-quality and affordable medications to improve the lives of patients worldwide. The company invests millions of dollars annually in research and development of new drugs to provide people with innovative and better treatment options. Various Divisions Dr. Reddy's Laboratories is divided into several business divisions, including: - Generics: A key business factor is generic production, including various dosages and forms of oral solid or liquid medications. - Biosimilars: Dr. Reddy's Laboratories has several biosimilars in its portfolio, including Epoetin alfa, Darbepoetin alfa, and Pegfilgastim, used for treating various diseases and conditions. - Specialty Products: The company also offers a variety of specialty products, particularly in the field of oncology. Products Over the years, Dr. Reddy's Laboratories has developed many innovative, high-quality, and affordable medications. Some of the company's most well-known products include: - Omez: A popular gastric medication used to treat heartburn and reflux. - Norflox: An antibiotic used to treat bacterial infections. - Reditux: A biosimilar of the antibody Rituximab used in cancer treatment. - Librium: A medication used for anxiety and depression. Conclusion Dr. Reddy's Laboratories is a global company specializing in the research, development, and manufacturing of innovative, high-quality, and affordable medications. The company has a long history in generic production and the manufacturing of specialty products and biosimilars. Through its research and development programs, the company constantly strives to meet the needs of patients and provide them with better healthcare. Dr Reddy's Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Dr Reddy's Laboratories's EBIT

Dr Reddy's Laboratories's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Dr Reddy's Laboratories's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Dr Reddy's Laboratories's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Dr Reddy's Laboratories’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Dr Reddy's Laboratories Stock

How much did Dr Reddy's Laboratories achieve in EBIT for the current year?

In the current year, Dr Reddy's Laboratories has achieved an EBIT of 64.63 B INR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Dr Reddy's Laboratories.

How has the EBIT of Dr Reddy's Laboratories developed in recent years?

The EBIT of Dr Reddy's Laboratories has increased by 22.186% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Dr Reddy's Laboratories?

The EBIT of Dr Reddy's Laboratories is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Dr Reddy's Laboratories pay?

Over the past 12 months, Dr Reddy's Laboratories paid a dividend of 40 INR . This corresponds to a dividend yield of about 0.62 %. For the coming 12 months, Dr Reddy's Laboratories is expected to pay a dividend of 43.54 INR.

What is the dividend yield of Dr Reddy's Laboratories?

The current dividend yield of Dr Reddy's Laboratories is 0.62 %.

When does Dr Reddy's Laboratories pay dividends?

Dr Reddy's Laboratories pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Dr Reddy's Laboratories?

Dr Reddy's Laboratories paid dividends every year for the past 0 years.

What is the dividend of Dr Reddy's Laboratories?

For the upcoming 12 months, dividends amounting to 43.54 INR are expected. This corresponds to a dividend yield of 0.68 %.

In which sector is Dr Reddy's Laboratories located?

Dr Reddy's Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dr Reddy's Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dr Reddy's Laboratories from 8/28/2024 amounting to 40 INR, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Dr Reddy's Laboratories pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of Dr Reddy's Laboratories in the year 2023?

In the year 2023, Dr Reddy's Laboratories distributed 40 INR as dividends.

In which currency does Dr Reddy's Laboratories pay out the dividend?

The dividends of Dr Reddy's Laboratories are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dr Reddy's Laboratories

Our stock analysis for Dr Reddy's Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dr Reddy's Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.